Drug Trial Radar · NCT00372593
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
Last checked: Nov 20, 2026Latest source record: Mar 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,070
Actual
Start
Aug 2006
Primary completion
Aug 2013
Study completion Sep 30, 2020
Sponsor
- Lead sponsor
- Children's Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Sep 7, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 29 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as gemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving combination chemotherapy together with gemtuzumab may kill more cancer cells. It is not yet known whether combination chemotherapy is more effective with or without gemtuzumab in treating patients with newly diagnosed acute myeloid leukemia. PURPOSE: This randomized phase III trial is studying combination chemotherapy and gemtuzumab to see how well they work compared with combination chemotherapy alone in treating young patients with newly diagnosed acute myeloid leukemia.
Conditions
- Leukemia
Interventions
asparaginaseDrug
Given intramuscularly
cytarabineDrug
Given IV
daunorubicin hydrochlorideDrug
Given IV over 6 hours
etoposideDrug
Given IV over 1-4 hours
gemtuzumab ozogamicinDrug
Given IV over 2 hours
mitoxantrone hydrochlorideDrug
Given IV over 1 hour
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free Survival at 3 YearsTime frame: Time from study entry to time of induction failure, relapse, or death, assessed at 3 years
- Overall Survival at 3 YearsTime frame: Time from study entry, assessed at 3 years
Locations
198 sites in 6 countries. Site status is shown where the registry gives one.
UAB Comprehensive Cancer Center
Birmingham, Alabama
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama
Banner Desert Medical Center
Mesa, Arizona
Phoenix Children's Hospital
Phoenix, Arizona
Arizona Cancer Center at University of Arizona Health Sciences Center
Tucson, Arizona
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas
Southern California Permanente Medical Group
Downey, California
City of Hope Comprehensive Cancer Center
Duarte, California
Loma Linda University Cancer Institute at Loma Linda University Medical Center
Loma Linda, California
Childrens Hospital Los Angeles
Los Angeles, California
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
Los Angeles, California
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California
Children's Hospital Central California
Madera, California
Children's Hospital and Research Center Oakland
Oakland, California
Kaiser Permanente Medical Center - Oakland
Oakland, California
Children's Hospital of Orange County
Orange, California
Sutter Cancer Center
Sacramento, California
University of California Davis Cancer Center
Sacramento, California
Rady Children's Hospital - San Diego
San Diego, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Santa Barbara Cottage Children's Hospital
Santa Barbara, California
Jonathan Jaques Children's Cancer Center at Miller Children's Hospital
Torrance, California
Children's Hospital Center for Cancer and Blood Disorders
Aurora, Colorado
Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
Farmington, Connecticut
Yale Cancer Center
New Haven, Connecticut
Alfred I. duPont Hospital for Children
Wilmington, Delaware
Children's National Medical Center
Washington D.C., District of Columbia
Walter Reed Army Medical Center
Washington D.C., District of Columbia
Broward General Medical Center Cancer Center
Fort Lauderdale, Florida
Lee Cancer Care of Lee Memorial Health System
Fort Myers, Florida
University of Florida Shands Cancer Center
Gainesville, Florida
Memorial Cancer Institute at Memorial Regional Hospital
Hollywood, Florida
Nemours Children's Clinic
Jacksonville, Florida
University of Miami Sylvester Comprehensive Cancer Center - Miami
Miami, Florida
Miami Children's Hospital
Miami, Florida
Baptist-South Miami Regional Cancer Program
Miami, Florida
Florida Hospital Cancer Institute at Florida Hospital Orlando
Orlando, Florida
M.D. Anderson Cancer Center at Orlando
Orlando, Florida
Nemours Children's Clinic - Orlando
Orlando, Florida
Sacred Heart Cancer Center at Sacred Heart Hospital
Pensacola, Florida
Showing 40 of 198 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.